Trial Search Results

Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma

This pilot clinical trial studies perfusion computed tomography (CT) in predicting response to treatment in patients with advanced kidney cancer. Comparing results of diagnostic procedures done before, during, and after targeted therapy may help doctors predict a patient's response to treatment and help plan the best treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Siemens Healthcare QT


  • Device: perfusion computed tomography


Inclusion Criteria:

   - Suspected or biopsy-proven renal cell carcinoma

   - Treatment planned with sunitinib, pazopanib, sorafenib, bevacizumab, axitinib,
   nivolumab alone or in combination with an investigational agent

   - Ability to understand and willingness to sign a written informed consent document

Exclusion Criteria:

   - Serum creatinine greater than or equal to 1.7 mg/dL

   - Severe allergy to contrast agent

   - Any contraindication for undergoing a CT scan

   - Pregnancy or unwillingness to use preventative measures if a woman of child-bearing

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Yoriko Imae